West Pharmaceutical Services, Inc. raised its earnings guidance for the full year 2026. For the period, is increasing its full-year 2026 net sales guidance range to $3.295 billion to $3.350 billion, which continues to assume a mid-year close for the sale of SmartDose® 3.5mL to Abbvie, up from $3.215 billion to $3.275 billion. Reported net sales growth is now anticipated to be in the range of 7.2% to 9.0%. The company expects reported-diluted EPS (U.S. GAAP)
From $8.15 to $8.50.